THL Partners (“THL”), a premier private equity firm investing in middle-market growth companies, today announced that Bruce Robertson, Ph.D., is joining the firm as a Managing Director on its Healthcare investment team. Robertson will focus on sourcing, evaluating, and executing investments across medtech products and life science tools and diagnostics, and partnering with management teams to support growth.

Robertson joins THL from H.I.G. Capital, where he served as a Managing Director and led a team investing in growth and control transactions across medical devices, digital health, and diagnostics. He brings a combination of healthcare investing experience, technical training, and direct industry experience in medical devices.

“Bruce’s ability to assess both the technology behind a product and the business opportunity around it will be a tremendous asset to our team and the companies with which we partner,” said Joshua Nelson, Managing Director and Head of Healthcare at THL. “His experience investing in healthcare products businesses and working with their management teams strengthens our ability to identify compelling opportunities across medtech products, and life science tools and diagnostics.”

Robertson’s appointment strengthens THL’s investment capabilities across two of its healthcare Identified Sector Opportunities (“ISOs”): MedTech Products and Life Science Tools and Diagnostics. These areas encompass businesses that support advances in research, diagnosis and treatment through the products and tools they provide. Through its ISO approach, THL develops deep sector expertise in specific markets and pairs that knowledge with dedicated operating resources to help companies accelerate growth and improve performance.

“THL’s depth of sector expertise and commitment to helping management teams build their businesses make it an exciting place to continue my work in healthcare investing,” said Robertson. “Companies across medtech and life science tools and diagnostics have an important role to play in advancing research and improving patient care. I look forward to partnering with my new colleagues and management teams to help these businesses grow and expand the reach of their products.”

Robertson’s prior investments include Intact Vascular and Vesper Medical, both acquired by Philips; Apollo Endosurgery and Vertiflex, both acquired by Boston Scientific; Neuwave Medical, acquired by Johnson & Johnson; and RxSight.

Before H.I.G., Robertson served as a Managing Director at Toucan Capital, a healthcare products fund, and as a General Partner at GIV Venture Partners. Earlier in his career, he was Director of Business Development at IGEN International, a molecular diagnostics company. He began his career as an engineer and Research Manager at W.R. Grace & Co., focusing on medical devices.

Robertson holds a Ph.D. in Chemical Engineering from the University of Delaware, an M.B.A. with High Distinction from Harvard Business School, and both a B.S.E. in Chemical Engineering and a B.A. in Mathematics from the University of Pennsylvania.

THL has deployed over $8.7 billion in healthcare, including fund and co-investment capital, acquiring approximately 30 companies and supporting more than 170 add-on acquisitions. Together, these transactions represent approximately $33 billion in aggregate enterprise value. THL also recently closed its tenth flagship fund, including associated vehicles, with $6.35 billion in investable capital.

About THL Partners

THL Partners is a premier private equity firm investing in middle-market growth companies exclusively within Healthcare, Financial and Essential Services, and Technology. THL couples deep sector expertise with dedicated operating resources to build great companies of lasting value in partnership with management teams. For more information, visit www.thl.com.

Media gallery

About The Author
Business Wire